<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00223</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Principal Investigators should submit the following materials to the Office of Recombinant DNA Activities, National Institutes of Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496&hyph;9838.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;III&hyph;A&hyph;1. Written proposals shall be submitted in the following order:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (1) Scientific abstract_1 page; (2) non-technical abstract_1 page; (3) Institutional Biosafety Committee and Institutional Review Board approvals and their deliberations pertaining to your protocol; (4) Response to Points to Consider_5 pages (see Appendix M through M&hyph;III); (6) protocol_20 pages excluding appendices_approved by the local Institutional Biosafety Committee and Institutional Review Board); (7) Informed Consent document_approved by the  <!-- PJG 0012 frnewline --> Institutional Review Board; (8) appendices including tables, figures, and  <!-- PJG 0012 frnewline --> manuscripts; (9) curricula vitae_2 pages for each key professional person in  <!-- PJG 0012 frnewline --> biographical sketch format; and (10) an indication of other Federal agencies to which the protocol is being submitted for review.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;III&hyph;A&hyph;2. When a proposal has been submitted previously, there should be a short section (&gt; 200 words) immediately following the abstracts that summarizes the major revisions since the last review.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;III&hyph;A&hyph;3. Data provided shall include: (i) A description of the  <!-- PJG 0012 frnewline --> elements in the vector, (ii) the source of that information, (iii) the method by which sequence data were compiled, and (iv) three 31/2 inch diskettes with the vector sequence in ASCII format.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Appendix M&hyph;III&hyph;B. Time Frame for Submissions  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Note:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Time frames are applicable only to protocols that are determined by NIH/ORDA to require full RAC review and NIH Director approval. Time frames do not apply to  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Accelerated  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Review human gene transfer experiments (see Section III&hyph;B&hyph;2 or those that only require registration with NIH/ORDA (see Section III&hyph;C&hyph; 7).  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;III&hyph;B&hyph;1. Written material from Principal Investigator shall be  <!-- PJG 0012 frnewline --> submitted &gt; 8 weeks before the RAC meeting at which it will be reviewed.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;III&hyph;B&hyph;2. Written comments from the primary reviewers to the Principal Investigator shall be submitted &gt; 4 weeks before the RAC meeting at  <!-- PJG 0012 frnewline --> which it will be reviewed.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;III&hyph;B&hyph;3. Written responses (including critical data in response to the primary reviewers' comments) shall be submitted by the Principal Investigator to NIH/ORDA &gt; 2 weeks before the RAC meeting.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            